Immunotherapy in Non-Small-Cell Lung Cancer Patients With Performance Status 2: Clinical Decision Making With Scant Evidence

J Clin Oncol. 2019 Aug 1;37(22):1863-1867. doi: 10.1200/JCO.18.02118. Epub 2019 Apr 17.

Authors

Antonio Passaro¹, Gianluca Spitaleri¹, Bishal Gyawali^{2

3}, Filippo de Marinis¹

Affiliations

¹ 1European Institute of Oncology, IRCCS, Milan, Italy.
² 2Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
³ 3Queen's Cancer Research Institute, Kingston, Ontario, Canada.

PMID: 30995172
DOI: 10.1200/JCO.18.02118

No abstract available

MeSH terms

Carcinoma, Non-Small-Cell Lung / complications
Carcinoma, Non-Small-Cell Lung / therapy*
Clinical Decision-Making
Decision Support Systems, Clinical
Drug Approval
Humans
Immunologic Factors / therapeutic use
Immunotherapy / methods*
Immunotherapy / standards
Lung Neoplasms / complications
Lung Neoplasms / therapy*
Medical Oncology / standards
Prognosis
Pulmonary Disease, Chronic Obstructive / complications
Randomized Controlled Trials as Topic
Treatment Outcome
United States

Substances

Immunologic Factors